These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26086178)

  • 1. Serum levels of tumor necrosis factor-related apoptosis-inducing ligand correlate with the severity of pulmonary hypertension.
    Liu H; Yang E; Lu X; Zuo C; He Y; Jia D; Zhu Q; Yu Y; Lv A
    Pulm Pharmacol Ther; 2015 Aug; 33():39-46. PubMed ID: 26086178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble tumor necrosis factor related apoptosis inducing ligand level as a predictor of severity of sepsis and the risk of mortality in septic patients.
    Tian Y; Tao T; Zhu J; Zou Y; Wang J; Li J; Bo L; Deng X
    PLoS One; 2013; 8(12):e82204. PubMed ID: 24349222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients.
    Liabeuf S; Barreto DV; Barreto FC; Chasseraud M; Brazier M; Choukroun G; Kamel S; Massy ZA
    Nephrol Dial Transplant; 2010 Aug; 25(8):2596-602. PubMed ID: 20190248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus.
    Lub-de Hooge MN; de Vries EG; de Jong S; Bijl M
    Ann Rheum Dis; 2005 Jun; 64(6):854-8. PubMed ID: 15564310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with IFNalpha in vivo up-regulates serum-soluble TNF-related apoptosis inducing ligand (sTRAIL) levels and TRAIL mRNA expressions in neutrophils in chronic myelogenous leukemia patients.
    Tanaka H; Ito T; Kyo T; Kimura A
    Eur J Haematol; 2007 May; 78(5):389-98. PubMed ID: 17432976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of soluble tumour necrosis factor-related apoptosis-inducing ligand levels with coronary plaque burden and composition.
    Deftereos S; Giannopoulos G; Kossyvakis C; Kaoukis A; Raisakis K; Panagopoulou V; Miliou A; Theodorakis A; Driva M; Pyrgakis V; Stefanadis C; Cleman MW
    Heart; 2012 Feb; 98(3):214-8. PubMed ID: 21965221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of post-cardioversion transcardiac concentration gradient of soluble tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL) and inflammatory biomarkers to atrial fibrillation recurrence.
    Deftereos S; Giannopoulos G; Kossyvakis C; Raisakis K; Angelidis C; Efremidis M; Panagopoulou V; Kaoukis A; Theodorakis A; Toli K; Zavitsanakis P; Mantas I; Pyrgakis V; Stefanadis C; Cleman MW
    Clin Biochem; 2013 Aug; 46(12):1020-1025. PubMed ID: 23481489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlations of genetic polymorphisms of tumor necrosis factor-related apoptosis-inducing ligand gene and its plasma phenotype with ulcerative colitis].
    Jiang Y; Lin XQ; Cao SG; Xu CL; Wang JZ; Huang ZM; Chen XR; Song L; Xue ZX
    Zhonghua Yi Xue Za Zhi; 2012 May; 92(18):1244-8. PubMed ID: 22883061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of soluble tumor necrosis factor-related apoptosis-inducing ligand concentrations after stem cell transplantation.
    Nomura S; Ishii K; Inami N; Uoshima N; Ishida H; Yoshihara T; Kitayama H; Hayashi K
    Transpl Immunol; 2007 Nov; 18(2):115-21. PubMed ID: 18005854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Up regulation of serum tumor necrosis factor-related apoptosis inducing ligand in juvenile-onset systemic lupus erythematosus: relations with disease activity, antibodies to double -stranded DNA, nephritis and neutropenia.
    Ezzat MH; El-Gammasy TM; Shaheen KY; El-Mezdawi RA; Youssef MS
    Int J Rheum Dis; 2013 Jun; 16(3):310-8. PubMed ID: 23981753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis.
    Michowitz Y; Goldstein E; Roth A; Afek A; Abashidze A; Ben Gal Y; Keren G; George J
    J Am Coll Cardiol; 2005 Apr; 45(7):1018-24. PubMed ID: 15808757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor-related apoptosis-inducing ligand and vascular calcification.
    Chasseraud M; Liabeuf S; Mozar A; Mentaverri R; Brazier M; Massy ZA; Kamel S
    Ther Apher Dial; 2011 Apr; 15(2):140-6. PubMed ID: 21426505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum-soluble TRAIL: a potential biomarker for disease activity in myositis patients.
    Zhou H; Wang Y; Bi K; Qi H; Song S; Zhou M; Chen L; Wang G; Duan T
    Clin Rheumatol; 2019 May; 38(5):1425-1431. PubMed ID: 30645753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The relationship between serum soluble apoptosis marker (sTRAIL) concentration and nutritional parameters in hemodialyzed patients].
    Wyrwicz-Zielińska G; Fedak D; Kuźniewski M; Pawlica D; Kuśnierz-Cabala B; Solnica B; Janda K; Sułowicz W
    Przegl Lek; 2013; 70(7):427-30. PubMed ID: 24167941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of apoptosis markers in advanced heart failure patients.
    Niessner A; Hohensinner PJ; Rychli K; Neuhold S; Zorn G; Richter B; Hülsmann M; Berger R; Mörtl D; Huber K; Wojta J; Pacher R
    Eur Heart J; 2009 Apr; 30(7):789-96. PubMed ID: 19196721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tumor necrosis factor-related apoptosis-inducing ligand gene polymorphism and its plasma phenotype in relation to Crohn's disease].
    Zhu HQ; Hu P; Xu F; Shao XX; Cao SG; Wu H; Jiang Y
    Zhonghua Yi Xue Za Zhi; 2023 Feb; 103(8):585-593. PubMed ID: 36822870
    [No Abstract]   [Full Text] [Related]  

  • 17. IL8 and serum soluble TRAIL levels following anti-VEGF monoclonal antibody treatment in patients with metastatic colon cancer.
    Kargi A; Yalcin AD; Erin N; Savas B; Polat HH; Gorczynski RM
    Clin Lab; 2012; 58(5-6):501-5. PubMed ID: 22783581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erratum to "IL8 and serum soluble TRAIL levels following anti-VEGF monoclonal antibody treatment in patients with metastatic colon cancer" [Clin. Lab. 2012; 58:501-505].
    Kargi A; Yalcin AD; Erin N; Savas B; Polat HH; Gorczynski RM
    Clin Lab; 2012; 58(9-10):1103-7. PubMed ID: 23163132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C.
    Pelli N; Floreani A; Torre F; Delfino A; Baragiotta A; Contini P; Basso M; Picciotto A
    Clin Exp Immunol; 2007 Apr; 148(1):85-9. PubMed ID: 17302732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autosomal Dominant Polycystic Disease is Associated with Depressed Levels of Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand.
    Sarı F; Yalçın AD; Genç GE; Sarıkaya M; Bisgin A; Çetinkaya R; Gümüşlü S
    Balkan Med J; 2016 Sep; 33(5):512-516. PubMed ID: 27761278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.